cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arbutus Biopharma Corporation
34 own
65 watching
Current Price
$2.9
$-0.05
(-1.69%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
442.86M
52-Week High
52-Week High
3.64
52-Week Low
52-Week Low
1.85
Average Volume
Average Volume
0.71M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization442.86M
icon52-Week High3.64
icon52-Week Low1.85
iconAverage Volume0.71M
iconDividend Yield--
iconP/E Ratio--
What does the Arbutus Biopharma Corporation do?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically infected with HBV. Its HBV product candidates also comprise ARB-1740, a RNAi HBV candidate that is in preclinical studies; small molecule cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; HBV core protein assembly inhibitors; ARB-1598, a toll-like receptor; surface antigen secretion inhibitors; cccDNA epigenetic modifiers; stimulator of interferon genes agonists; and cyclophilin inhibitor drug candidates, including OCB-030 and other cyclophilin inhibitors. In addition, it develops TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02,whichis in Phase III clinical study, a therapeutic targeting transthyretin mediated amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for treating Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Read More
How much money does Arbutus Biopharma Corporation make?
News & Events about Arbutus Biopharma Corporation.
Globe Newswire
9days ago
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has notified ...
Globe Newswire
1month ago
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa., ...
Ticker Report
2 months ago
Arbutus Biopharma (NASDAQ:ABUS Get Rating) had its price target reduced by HC Wainwright from $7.50 to $6.00 in a research report report published on Thursday morning, The Fly reports. They currently have a buy rating on the biopharmaceutical companys stock. Separately, StockNews.com ...
Globe Newswire
2 months ago
Financially strong with a projected cash runway into thesecond quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before year ...
Globe Newswire
4 months ago
WARMINSTER, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Gaston Picchio, PhD, Chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Arbutus Biopharma Corporation share price today?
plus_minus_icon
Can Indians buy Arbutus Biopharma Corporation shares?
plus_minus_icon
How can I buy Arbutus Biopharma Corporation shares from India?
plus_minus_icon
Can Fractional shares of Arbutus Biopharma Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Arbutus Biopharma Corporation stocks?
plus_minus_icon
What is today’s traded volume of Arbutus Biopharma Corporation?
plus_minus_icon
What is today’s market capitalisation of Arbutus Biopharma Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Arbutus Biopharma Corporation?
plus_minus_icon
What percentage is Arbutus Biopharma Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Arbutus Biopharma Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$2.9
$-0.05
(-1.69%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00